New Issue: RBC prices $3.08 million return optimization notes tied to eight stocks

By Angela McDaniels

Tacoma, Wash., June 26 – Royal Bank of Canada priced $3.08 million of 0% return optimization securities due July 31, 2015 linked to a basket of stocks, according to a 424B2 filing with the Securities and Exchange Commission.

The basket includes equal weights of BioMarin Pharmaceutical Inc., Celgene Corp., Gilead Sciences, Inc., Incyte Corp., Medivation, Inc., Merck & Co., Inc., Pfizer Inc. and Puma Biotechnology, Inc.

If the basket return is positive, the payout at maturity will be par of $10 plus 300% of the basket return, subject to a 29% maximum return. If the basket return is negative, investors will have one-to-one exposure to the decline.

UBS Financial Services Inc. and RBC Capital Markets, LLC are the agents.

Issuer:	Royal Bank of Canada
Issue:	Return optimization securities
Underlying stocks:	BioMarin Pharmaceutical Inc., Celgene Corp., Gilead Sciences, Inc., Incyte Corp., Medivation, Inc., Merck & Co., Inc., Pfizer Inc. and Puma Biotechnology, Inc., equally weighted
Amount:	$3.08 million
Maturity:	July 31, 2015
Coupon:	0%
Price:	Par of $10
Payout at maturity:	If basket return is positive, par plus 300% of basket return, subject to 29% maximum return; if basket return is negative, one-to-one exposure to decline
Pricing date:	June 25
Settlement date:	June 30
Agents:	UBS Financial Services Inc. and RBC Capital Markets, LLC
Fees:	None
Cusip:	78011Q584

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.